In a recent study, the clinical effects of A-MSC have been reported in a murine model of sclerosing cholangitis, where downregulation of cytokeratin (CK)-19, MMP-9, TNF-α, and monocyte chemoattractant protein-1 (MCP-1) have been described in association with improved pathological score [141]. This evidence concerns the gene CCL2 and sclerosing cholangitis.